IVERIC bio (IVERIC bio) Cash-to-Debt : 6.14 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. IVERIC bio's cash to debt ratio for the quarter that ended in Mar. 2023 was 6.14.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, IVERIC bio could pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.

The historical rank and industry rank for IVERIC bio's Cash-to-Debt or its related term are showing as below:

ISEE' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.14 Med: No Debt Max: No Debt
Current: 6.14

During the past 12 years, IVERIC bio's highest Cash to Debt Ratio was No Debt. The lowest was 6.14. And the median was No Debt.

ISEE's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs ISEE: 6.14

IVERIC bio Cash-to-Debt Historical Data

The historical data trend for IVERIC bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

IVERIC bio Cash-to-Debt Chart

IVERIC bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

253.94

1,826.50

243.00

6.62

IVERIC bio Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash-to-Debt	Get a 7-Day Free Trial															257.96	151.81	6.50	6.62	6.14

Competitive Comparison of IVERIC bio's Cash-to-Debt

For the Biotechnology subindustry, IVERIC bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IVERIC bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Cash-to-Debt falls into.

IVERIC bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

IVERIC bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	646.835	/	(1.189	+	96.579)
	=	6.62

IVERIC bio's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	599.921	/	(0.774	+	96.987)
	=	6.14

IVERIC bio (NAS:ISEE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

IVERIC bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

IVERIC bio (IVERIC bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, New Jersey, USA, 07054

Website

https://www.ivericbio.com

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

Executives

Keith Westby	officer: SVP & COO	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll	officer: SVP, CFO and Treasurer	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms	officer: Senior Vice President, CCO	FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney	officer: EVP, Chief Business Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller	director	5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel	officer: EVP, Chief Strategy & Business	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer	director, officer: Chief Executive Officer	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142